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21 ABSTRACT (225/250)
22 Objectives: Modifiable lifestyle factors are implicated in multiple sclerosis (MS) symptoms 23 but their role in mood is unclear. This study aims to investigate associations between 24 lifestyle and depression and anxiety in Australian participants with MS.25 Materials & Methods: Self-reported data from the Australian Multiple Sclerosis 26 Longitudinal Study included the Hospital Anxiety and Depression Scale (HADS) and lifestyle 27 measurements from 1,500 participants. SNAP score (range 0-5) was the sum of: non-28 smoking, sufficient fruit/vegetable intake, non-hazardous alcohol consumption, sufficient 29 physical activity, and healthy BMI. Analyses by log-binomial and linear regression were 30 adjusted for confounding.31 Results: Depression and anxiety was prevalent in 27% and 40%, respectively; 20% had 32 both. Mean SNAP score was 2.7/5; only 3% met all healthy lifestyle recommendations. Only 33 10% reported adequate fruit/vegetable intake, and 22% reported a combination of 34 unhealthy BMI, inadequate physical activity and inadequate nutrition.  A healthier SNAP 35 score was associated with lower depression prevalence (adjusted prevalence ratio 0.83 36 (95%CI 0.75, 0.92) per unit increase) and depression severity (adjusted β -0.44 (95%CI -37 0.64, -0.24)), but not with anxiety.38 Conclusions: Modifiable lifestyle factors are associated with lower frequency and severity 39 of depression, but not anxiety, in Australian people with multiple sclerosis. The 40 associations between a healthier SNAP score and lower depression are likely bi-directional. 
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41 SNAP risk factor prevalence and co-occurrence, especially inadequate nutrition and low 42 physical activity, was high among Australians with MS.4344 Keywords: multiple sclerosis; anxiety; depression; lifestyle; health behaviours; SNAP45
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46 INTRODUCTION 
47 Clinically significant symptoms of anxiety or depression are observed in up to 40% of 48 people with multiple sclerosis (MS)1, with prevalence estimates approximately twice that 49 of the general population2. It is possible that anxiety and depression arise from 50 inflammation of the CNS and are hence considered symptoms of MS, yet they can also be 51 considered comorbidities, secondary to the disease3. Both mood states have been 52 associated with increased level of disability4 and fatigue5. Stress responses associated with 53 anxiety, as well as depressive symptoms, have been associated with increased 54 inflammation and with exacerbations of MS6.5556 Current pharmacological or psychological treatments for depression are proven to be 57 generally effective in reducing clinically significant symptoms7 in most people with MS. 58 However, the effectiveness of anxiety treatments for people with MS has not been 59 established7. Furthermore, only half of all people with MS suffering from anxiety or 60 depression receive treatment for their condition2. 6162 Modifiable lifestyle factors such as smoking status, nutrition, alcohol consumption, physical 63 activity level and body mass index (BMI) make up the ‘SNAP’ score, a construct used in 64 general practice8. These SNAP factors are major determinants of morbidity, mortality, and 65 functionality in the general population9. Growing evidence suggests that these same SNAP 66 factors also play a major role in brain and mental health9. Whether there is an additive 
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67 effect from fulfilling more of these SNAP factors is unclear, given that few studies have 68 explored SNAP score in this populationpeople with MS.6970 The current study uses a representative sample of people with MS in Australia to 1) 71 describe the prevalence of SNAP risk factors and their co-occurrence; 2) investigate 72 whether SNAP score is associated with the prevalence and severity of anxiety and 73 depression.74
75 MATERIALS & METHODS 
76 All data was sourced from the Australian Multiple Sclerosis Longitudinal Study (AMSLS). 77 The sample is large, representative and generalisable to the Australian MS population10. To 78 be eligible for the study, an individual must have a diagnosis of MS, be over 18 years of 79 age, and live in any Australian state or territory. The study was approved by the Tasmanian 80 Health and Medical Human Research Ethics Committee and all participants provided 81 informed consent. The 2016 AMSLS Lifestyle survey was conducted from August to October 82 2016. Invitations were sent to all 3112 active participants (2182 online surveys and 930 83 paper surveys), and 1518 (48.78 %) participants responded to the survey (1067 online and 84 451 paper surveys). Non-response analyses showed no significant difference in sex 85 (p=0.101) and education level (p=0.113) between the respondents and non-respondents, 86 while the respondents were slightly older (+1.49 years, p<0.01) and had a slightly longer 
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87 MS duration since diagnosis (+0.56 years, p=0.04). These differing factors were evaluated 88 in multivariable models to control for the potential bias in participation.8990 SNAP Score91 SNAP – comprised of smoking, nutrition, alcohol and physical activity – was first proposed 92 as part of a policy framework tool by the Australian Government in 2001 for use in general 93 practice8. SNAP has previously been used in a North American sample of people with MS to 94 estimate prevalence of lifestyle risk factors11. The five factors comprising the SNAP score in 95 our study were modelled onfrom this study11 and another more recente previous study12 96 both using similar aggregate scores, dy11 with minor deviations to suit the Australian SNAP 97 guidelines. , andOur aggregate SNAP score included smoking status, diet (assessed by the 98 Diet History Questionnaire, DHQ13), alcohol consumption, physical activity level (assessed 99 by the International Physical Activity Questionnaire, IPAQ14), and BMI (estimated from self-100 reported height and weight, as weight (kg)/height (m)2), each coded as binary variables. To 101 achieve a score for non-smoker, an individual had to report smoking less than one 102 cigarette, cigar or pipe per day. A healthy diet was defined as consuming ≥5 serves of 103 vegetables/day and ≥2 serves of fruit at least six days/week, as per the Australian Dietary 104 Guidelines15. Non-hazardous alcohol consumption required consuming ≤2 standard 105 alcoholic drinks/day, the national recommendation16. Adequate level of physical activity 106 was defined as moderate/high (versus low) level  of physical activity as scored per the IPAQ 107 guidelines14. A healthy BMI was defined as within the healthy BMI range (18.5 kg/m2 to 
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108 24.9 kg/m2) as opposed to underweight (below 18.5 kg/m2), overweight (25 kg/m2 to 29.9 109 kg/m2) or obese (30.0 kg/m2 and above)17.110111 Anxiety and Depression112 The Hospital Anxiety and Depression Scale (HADS)18 was used to measure cognitive and 113 emotional symptoms of anxiety and depression. The HADS, and has been validated for use 114 in people with MS for to measure depression and generalised anxiety19. The two subscales 115 of the HADS, anxiety and depression, each ranged had a range of 0-21 and , which wasere 116 evaluated to assess associations with depression/anxiety severity. The HADS threshold for 117 mild symptoms (≥8) was used to determine whether an individual showed clinically 118 significant symptoms of anxiety or depression18. 119120 Other data collected included age, sex, MS type, disability measured by the Patient-121 Determined Disease Steps (PDDS) scale20, fatigue measured by the Fatigue Severity Scale 122 (FSS)21, disease duration since symptom onset, MS disease-modifying therapy use, 123 treatment for depression or anxiety, number of previous or current comorbidities 124 (including a list of 30 common chronic medical conditions and a “other” free text option), 125 education level, employment status, remoteness, and socioeconomic status measured by 126 the SEIFA Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD)22. 127
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128 Statistical Analyses129 Associations with prevalent anxiety/depression were assessed using log-binomial 130 regression, estimating a prevalence ratio. Associations with severity of anxiety and 131 depression symptoms were assessed by linear regression. Polytomous independent 132 variables were evaluated as predictors of outcomes using log-binomial regression, the 133 stratum-specific values using an interaction-expansion operator. For ordinal polytomous 134 independent variables, in addition to the stratum-specific estimates of association, the 135 regression was also run without the interaction expansion operator, thus evaluating the 136 categorical term as a continuous variable. The significance of this association denoted the 137 test for trend. All models were adjusted for age, sex, disability, fatigue, depression/anxiety 138 treatment, education, and socioeconomic status. These confounders were identified via a 139 directed acyclic graph (DAG), which was created using relevant literature according to best 140 practice epidemiological methods23factors selected based on literature review. All analyses 141 were complete case analysisanalyses, meaning; that is, only those with complete SNAP, 142 anxiety and depression data were included in analyses. Analyses wereis was conducted 143 using STATA 13.0 (StataCorp, College Station, USA). 144
145 RESULTS
146 1500 participants completed enough data to be included in this study. The majority of 147 participants were female (79.5%), unemployed (60.4%), used disease-modifying therapies 148 (62.4%) and had relapsing-remitting MS (61.9%) (Table 1). Almost half of the sample had a 
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149 mild level of disability as defined by PDDS<3 (47.6%). Comorbidities were experienced by 150 the vast majority of participants (91.1%), with some reporting more than ten 151 comorbidities. Those with complete SNAP, anxiety and depression data were similar to 152 those with incomplete data, except that those lacking with incomplete data were more 153 likely to be severely disabled and receiving treatment for depression (Table 1). Over one-154 third of participants had clinically significant symptoms of anxiety and roughly one-quarter 155 had clinically significant symptoms of depression; one-fifth had both anxiety and 156 depression.157158 [Insert Table 1 here]159160 SNAP Factors161 Most participants did not smoke (89.6%) and reported alcohol consumption within 162 recommended levels (82.9%; Table 2). Around 10% of the sample consumed the 163 recommended daily intake of fruit and vegetables, with 33.1% meeting the fruit 164 consumption targets and 17.0% meeting the vegetable consumption targets. Just over half 165 of participants engaged in adequate physical activity (52.9%), while 39% had a healthy BMI.166167 [Insert Table 2 here]168  
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169 SNAP Risk Factor Co-occurrence170 The most common combination of SNAP risk factors was unhealthy BMI, inadequate 171 physical activity and inadequate nutrition, observed in almost one-quarter of the 172 participants (22.2%; Figure 1). Of those with just one SNAP risk factor, poor diet was the 173 most common, with 14.0% meeting all other SNAP factor recommendations except for 174 consumption of the recommended daily intake of fruit and vegetables. 175176 [Insert Figure 1 here]177178 SNAP Protective Factor co-occurrence 179 Only 3.0% of the sample met all five SNAP protective factor recommendations, while 0.8% 180 met none at all (Table 3) 181182 [Insert Table 3 here]Figure 1).183184 Anxiety and depression185 Anxiety was less prevalent with increasing age, and more prevalent in females compared to 186 males (Table 43). Participants with moderate or severe disability had a roughly 2-fold 187 greater prevalence of depression, but for anxiety there was no consistent relationship with 188 disability. Prevalent fatigue, however, was associated with a higher prevalence of anxiety 189 and depression. Progressive-onset MS was associated with a greater prevalence of 
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190 depression compared to relapse-onset MS. Those with more comorbidities were more 191 likely to have anxiety and depression. Education, employment and socioeconomic status 192 were associated with lower prevalence of depression, but none were significantly 193 associated with anxiety. Participants reporting anxiety and/or depression treatment were 194 more likely to have anxiety and depression.195196 [Insert Table 4 3 here]197198 SNAP Protective Factors and Anxiety & Depression199 Non-smokers and those engaging in adequate physical activity had lower prevalence of 200 depression and lower HADS-Depression scores (Table 54). Participants who met the 201 recommendations for healthy diet had lower HADS-Depression scores. Those who reported 202 non-hazardous consumption of alcohol had a lower prevalence of depression. Non-203 smoking status was associated with a lower anxiety severity, but none of the other 204 individual SNAP protective factors were significantly associated with , but no other lifestyle 205 factors were significantly associated with aanxiety severity or prevalence. 206207 [Insert Table 5 4 here]208209 Higher SNAP score showed a significant and dose-dependent inverse relationship with 210 depression prevalence and severity, such that those with a SNAP score of 4-5 had 43% 211 lower prevalence of depression and 1.57-points lower HADS-Depression score compared to 
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212 those with a SNAP score of 0-1. When analyzing the SNAP score as a continuous variable, 213 every unit increase in SNAP score was associated with a 17% reduction in prevalent 214 depression and a 0.44 unit lower actual HADS depression score. While there was some 215 indication of an inverse relationship between SNAP score and anxiety severity, this was of 216 poor dose-dependency and did not reach statistical significance. 217
218 DISCUSSION
219 This is the first study examiningThis study examined the association between an aggregate 220 lifestyle score and depression & anxiety using data from a representative sample of people 221 with MS in Australia. A healthier lifestyle, as measured by a higher SNAP score, was 222 associated with a lower prevalence and severity of depression. No significant associations 223 were observed with the prevalence and severity of anxiety.224225 Depression was common (27%) and associated with SNAP risk factors smoking, alcohol 226 consumption and physical inactivity, while depression severity was associated with 227 smoking, inadequate nutrition and physical inactivity. The associations persisted after 228 adjustment for age, sex, disability, treatment for depression, education level and 229 socioeconomic status. Every unit increase in SNAP score was associated with a 17% 230 reduction in prevalent depression and a 0.44 unit lower actual HADS depression score. The 231 findings are in line with previous work showing that smoking and poor diet were associated 232 with increased risk of depression in people with MS24. Research into the mechanisms 
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233 between diet and mood is still emerging, but evidence for this association is strong within 234 the general population25. Observational studies in people with MS have consistently shown 235 an association between physical inactivity and depression26 as well as excessive alcohol use 236 and depression27, so our results here are in keeping with these prior findings. We did not 237 find an association between BMI and depression prevalence or severity, however, which is 238 inconsistent with previous studies24,28. Potentially tThis could reflect the self-reported 239 nature of the height/weight, with errors potentially affecting these associationsdifferences 240 in study design or populations, however, this is mere speculation and more research is 241 needed to clarify this. 242243 The underlying mechanisms, and causality, of these associations cannot be disentangled 244 from our data. On the one hand, research has shown that individuals experiencing clinically 245 significant depression are more likely to engage in poor health behaviours29 and may be 246 less likely to have the motivation to engage in healthy lifestyle behaviours or be proactive 247 about their health. Treating the depression may then also result in a reduction of 248 modifiable risk factors, which may have flow-on effects for general health. This mechanism 249 likely accounts for some of the association we observed between SNAP score and 250 depression. However, on the other hand, a combination of lifestyle risk factors may also 251 contribute to the risk for depression. Modifying these risk factors may then also see a 252 decrease in depression. Indeed, exercise has been shown to be effective in treating 253 depression in people with MS30. Both mechanisms may be at play simultaneously and it is 254 likely that for those with depression a feedback loop exists, whereby the risk for depression 
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255 is increased by poor health behaviours, while depressive symptoms increase the risk for 256 poor health behaviours, and so on. Sophisticated feedback loops for depression including 257 health behaviours have been described in the literature30, and a further understanding of 258 these may improve both depressive symptoms and health behaviours.   259260 Anxiety was very common (40%) and anxiety symptom severity was associated with 261 smoking, in line with a previous prospective study in people with MS31, though an inverse 262 association with anxiety prevalence did not reach significance. However, no other 263 associations were found between individual SNAP protective factors or SNAP score and 264 anxiety prevalence or symptom severity. In contrast to the results for depression, we did 265 not find an association between SNAP score and anxiety prevalence or symptom severity. 266 Far less is known about the association between anxiety and modifiable lifestyle factors in 267 people with MS given that anxiety disorders are often overlooked and under-treated in this 268 population2. One study found that people with MS who have a history of excessive alcohol 269 consumption have a higher lifetime prevalence of anxiety32 and another found that people 270 with MS with obesity are more likely to have anxiety28. There is evidence that the SNAP 271 protective factors are associated with anxiety in other populations, such as those with 272 cardiovascular disease33. Health anxiety, or anxiety about one’s health, overlaps with 273 generalised anxiety in symptomology and has a much greater prevalence in people with 274 MS compared to the general population35, which may suggest that participants may be 275 anxious about their health and therefore proactive in achieving the recommended 276 requirements for the SNAP protective factors.
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277278 We found that SNAP risk factors were common, in line with previous studies in the United 279 States11,34.  The vast majority of people with MS are not consuming the recommended daily 280 requirement of fruit and vegetables (90%), with proper vegetable intake being the most 281 infrequent. The proportions of people with MS who were overweight or obese (58%), had 282 hazardous consumption of alcohol (17%) or smoked (10%), were similar to those of 283 previous studies11. Interestingly, however, physical activity levels in this sample were 284 slightly higher compared to a previous study11.  Inadequate nutrition, physical inactivity 285 and unhealthy BMI was the most common combination of SNAP risk factors (22%)11.286287 Strengths and Limitations288 This study benefits from a large sample size and broad and validated representativeness, 289 both to the general Australian population and particularly to the MS population. 290 Accordingly, the generalisability of these results is manifest. The comprehensive 291 measurement of multiple demographic, clinical and lifestyle factors gives us great capacity 292 to control for relevant confounding variables so as to assess the independence of the 293 observed associations. A key limitation of the present analysis is its cross-sectional nature, 294 thus precluding ascription of causal directionality. Likely there exists bi-directionality and 295 further prospective cohort or randomised trial studies are needed to assess the causal 296 direction of these associations, given that retrospective measures of modifiable lifestyle 297 factors were not included as part of the current study.298
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299 The lack of association found between SNAP score and anxiety could be due to the fact 300 that the HADS does not differentiate between different types of anxiety, but instead 301 observes cognitive and emotional aspects of generalised anxiety19. The HADS measure may 302 not have the specificity to detect other types of anxiety disorders, yet the association 303 between SNAP score and anxiety and depression may differ between disorders.304305 All variables used in the analyses were self-reported, including all measures used for the 306 SNAP score and the HADS. Due to the size of the study, it was not feasible to extract 307 objective measures for every participant. This possibly introduced differential exposure 308 measurement error, meaning that those with anxiety and/or depression may report their 309 engagement in SNAP protective factors differently to those without anxiety and/or 310 depression. Not enough is known about the direction of this bias to infer its effect on the 311 association between SNAP protective factors and anxiety and depression. Selection bias 312 may have resulted in an under-estimated prevalence of depression and/or anxiety, given 313 that people with more severe symptoms of depression and/or anxiety may be less likely to 314 participate in the survey. Distance from relapse may have negatively impacted mood or 315 engagement in modifiable lifestyle behaviours, however these data were not assessed. We 316 included number of comorbidities as an aggregate covariable, created using Australian 317 National Healthy Survey data to ensure a wide range of common chronic medical 318 conditions were included35. Analyses of each comorbidity type was beyond the scope of 319 this study.320
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321 Implications of Findings322 The high prevalence and co-occurrence of SNAP risk factors in this study was high, 323 consistent with previous studies, and warrants increased health assessment and referrals 324 by healthcare professionals, especially in people with MS and depression. It is likely that 325 the presence of depressive symptoms will be accompanied by poor lifestyle behaviours, 326 overweight or obesity. Anxiety and depression are common and often co-occur. However, 327 these should be treated as separate and very unique constructs in this population, given 328 their markedly different prevalence, as well as the diverse associations between SNAP 329 score and anxiety and depression observed. Investigation of barriers faced by people with 330 MS in improving health behaviours has identified fatigue, physical impairment and side 331 effects of MS and associated medications36 and these need to be assessed and addressed 332 on an individual basis. The utility of the SNAP score may vary across the disease course. 333 Longitudinal assessment of lifestyle modification among participants with greater and 334 lesser degrees of disease severity would be informative.335336 Conclusion337 We found that SNAP protective factors and a healthier SNAP score were associated with a 338 lower depression prevalence and severity, while no associations were seen for anxiety. The 339 present study is the first to provide evidence that there is a high prevalence of anxiety and 340 depression in a representative sample of Australian people with MS and that many are not 341 meeting health recommendations. Investigation of the co-occurrence of SNAP risk factors 342 in this population showed that a combination of unhealthy BMI, poor diet and inadequate 
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343 physical activity is common. Given that SNAP risk factors, anxiety and depression all 344 contribute significantly to the morbidity of MS, efforts to improve the lifestyle and mental 345 health outcomes for an individual with MS should be holistic and all-inclusive. Future 346 prospective studies should elucidate the direction of association between depression and 347 SNAP protective factors, alongside investigation of the viability of multi-modal lifestyle 348 modification to treat depressive symptoms in this population. 349
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Table 1. Demographic characteristics of the 1,500 participants with multiple sclerosis included in the study.
.
Characteristic
Total Missing Outcome or Exposure Data
Outcome and 
Exposure Data 
Available
Mean SD Mean SD Mean SD p-value
Age, years 56.0 11.2 56.2 11.8 56.0 11.1 0.80
SNAP score 2.7 0.90 2.7 0.87 2.7 0.90 0.16
Median IQR Median IQR Median IQR p-value
Years since symptoms onset 13.0 10.0 13.0 10.0 13.0 10.0 0.44
Comorbidity number 3.0 3.0 3.0 3.0 3.0 3.0 0.88
N % N % N % p-value
Female sex 1,192 79.5% 274 83.0% 918 78.5% 0.07
PDDS
Mild (1-3) 569 37.9% 20 6.1% 549 46.9% [ref]
Moderate (4-6) 412 27.5% 9 2.7% 403 34.4% 0.23
Severe (7-9) 214 14.3% 15 4.6% 199 17.0% 0.04
(missing) 305 20.3% 286 86.7% 19 1.6% <0.001
Type of MS at onset
Relapse-onset MS 858 57.2% 28 8.5% 830 70.9% [ref]
Progressive-onset MS 119 7.9% 6 1.8% 113 9.7% 0.33
(missing) 523 34.9% 296 89.7% 227 19.4% <0.001
Type of MS now
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Primary-progressive MS 97 8.7% 5 12.2% 92 8.6% 0.37
Relapsing-remitting MS 691 61.9% 23 56.1% 668 62.1% [ref]
Secondary-progressive MS 167 15.0% 5 12.2% 162 15.1% 0.83
Progressive-relapsing MS 22 2.0% 1 2.4% 21 2.0% 0.76
Unsure 139 12.5% 7 17.1% 132 12.3% 0.33
Prevalent anxiety (HADS-A ≥ 8) 483 39.8% 20 44.4% 463 39.6% 0.51
Prevalent depression (HADS-D ≥ 8) 332 27.3% 10 22.2% 322 27.5% 0.43
Anxiety and depression 237 19.5% 6 13.3% 231 19.7% 0.29
Employed 479 39.6% 12 26.1% 467 40.1% 0.06
DMT use 756 62.4% 23 53.5% 733 62.8% 0.22
Prevalent fatigue (FSS ≥ 5 ) 502 41.3% 23 48.9% 479 40.9% 0.28
Socioeconomic status
Low 428 28.5% 102 30.9% 326 27.9% 0.14
Medium 413 27.5% 96 29.1% 317 27.1% 0.21
High 659 43.9% 132 40.0% 527 45.0% [ref]
Depression treatment 353 23.5% 96 29.1% 257 22.0% 0.01
Anxiety treatment 204 13.6% 49 14.9% 155 13.3% 0.45
 
Abbreviations: DMT=Disease modifying therapies; IQR=Inter-quartile range; PDDS=Patient Determined Disease Steps; SD=Standard deviation.
Differences in normally distributed continuous variables assessed by Student’s t-test, while skewed continuous variables were assessed using 
Kruskal-Wallis rank sum test. Differences in categorical variables assessed by multinomial logistic regression. 
Results in boldface denote statistical significance.
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Table 2. SNAP factor prevalence.
SNAP factor N %
Smoking
At least one cigar/cigarette/pipe per day 156 10.4%
Less than one cigar/cigarette/pipe per day 1,344 89.6%
Diet
Insufficient fruit and vegetable intake 1,340 89.9%
Sufficient fruit and vegetable intake 151 10.1%
Consumption of alcohol
More than two standard drinks per day 256 17.1%
Two or less standard drinks per day 1,244 82.9%
Level of physical activity
Low in the last week 707 47.1%
Moderate or high in the last week 793 52.9%
Body Mass Index
Underweight, overweight or obese 883 61.0%
Healthy 564 39.0%
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Table 3. Prevalence ratios of prevalent anxiety and depression (HADS ≥ 8).
 Prevalence Ratio (95% Confidence Interval)
 Anxiety Depression
Age (years)
0-49 1.00 [ref] 1.00 [ref]
50-59 0.80 (0.67, 0.94) 1.19 (0.94, 1.51)
60-64 0.86 (0.71, 1.05) 1.27 (0.97, 1.67)
65+ 0.67 (0.55, 0.82) 0.93 (0.70, 1.22)
P-trend <0.001 0.68
Sex (female) 1.32 (1.09, 1.61) 0.94 (0.76, 1.18)
Type of MS at onset
Remitting-onset MS 1.00 [ref] 1.00 [ref]
Progressive-onset MS 1.17 (0.95, 1.45) 1.34 (1.02, 1.75)
Type of MS now
Primary-progressive MS 1.00 [ref] 1.00 [ref]
Relapsing-remitting MS 0.94 (0.74, 1.21) 0.70 (0.51, 0.95)
Secondary-progressive MS 0.88 (0.65, 1.19) 1.09 (0.78, 1.53)
Progressive-relapsing MS 1.51 (1.02, 2.23) 1.20 (0.68, 2.13)
Unsure 0.73 (0.52, 1.03) 0.80 (0.55, 1.18)
PDDS
Mild disability 1.00 [ref] 1.00 [ref]
Moderate disability 1.39 (1.20, 1.62) 2.07 (1.66, 2.59)
Severe disability 1.01 (0.81, 1.24) 2.28 (1.78, 2.91)
P-trend 0.16 <0.001
Prevalent fatigue 1.80 (1.56, 2.06) 3.22 (2.63, 3.95)
Years since symptom onset
0-9 1.00 [ref] 1.00 [ref]
10-14 0.91 (0.76, 1.08) 1.01 (0.78, 1.30)
15-19 0.89 (0.73, 1.08) 1.17 (0.90, 1.53)
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20+ 0.71 (0.58, 0.88) 1.10 (0.85, 1.42)
P-trend 0.002 0.30
DMT use 1.07 (0.93, 1.24) 0.91 (0.76, 1.10)
Anxiety treatment 2.05 (1.81, 2.33) 1.71 (1.39, 2.11)
Depression treatment 1.55 (1.35, 1.78) 2.06 (1.72, 2.46)
Comorbidities
  0-2 1.00 [ref] 1.00 [ref]
      3-5 1.59 (1.33, 1.90) 1.65 (1.31, 2.09)
  6+ 2.07 (1.71, 2.50) 2.38 (1.85, 3.05)
  P-trend <0.001 <0.001
Highest education level
Primary School 1.00 [ref] 1.00 [ref]
Secondary School 1.46 (0.45, 4.75) 1.01 (0.31, 3.29)
Certificate or Diploma 1.46 (0.45, 4.74) 1.13 (0.35, 3.68)
Bachelor's Degree 1.31 (0.40, 4.26) 0.85 (0.26, 2.79)
Postgraduate Degree 1.24 (0.38, 4.08) 0.62 (0.18, 2.09)
P-trend 0.13 0.002
Employed 1.04 (0.91, 1.20) 0.66 (0.54, 0.81)
Socioeconomic status
Low 1.00 [ref] 1.00 [ref]
Medium 0.96 (0.81, 1.15) 0.85 (0.67, 1.07)
High 0.87 (0.74, 1.03) 0.72 (0.58, 0.89)
P-trend 0.097 0.003
Rurality
Major city 1.00 [ref] 1.00 [ref]
Regional 0.98 (0.85, 1.14) 1.14 (0.94, 1.37)
Remote 0.50 (0.14, 1.72) 0.76 (0.22, 2.64)
Abbreviations: DMT=Disease Modifying Therapies; MS=Multiple sclerosis; PDDS=Patient Determined 
Disease Steps; ref=Reference category.
Prevalence ratios estimated using log-binomial regression and are unadjusted.
Boldface values denote statistical significance (p<0.05).
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Table 4. Association between SNAP protective factors & SNAP score and occurrence and severity of anxiety & depression.
N % Anxiety Depression
Prevalence Ratio
Symptom Severity 
(Adjusted β1)
Prevalence Ratio
Symptom Severity 
(Adjusted β1)
Non-smoker 1,344 89.6% 0.83 (0.68, 1.00) -1.33 (-2.10, -0.55) 0.75 (0.59, 0.94) -1.12 (-1.76, -0.48)
Healthy diet 151 10.1% 0.92 (0.72, 1.18) -0.38 (-1.13, 0.36) 0.80 (0.57, 1.11) -0.81 (-1.42, -0.20)
Non-hazardous 
consumption of alcohol
1,244 82.9%
1.01 (0.84, 1.22) -0.19 (-0.80, 0.42) 0.79 (0.63, 0.99) -0.32 (-0.82, 0.19)
Adequate physical 
activity
793 52.9%
0.98 (0.85, 1.14) -0.13 (-0.62, 0.37) 0.70 (0.57, 0.87) -0.85 (-1.25, -0.44)
Healthy BMI 564 39.0% 1.03 (0.89, 1.18) 0.03 (-0.44, 0.49) 0.94 (0.78, 1.14) -0.16 (-0.54, 0.23)
SNAP score
0/1 115 8.0% 1.00 [ref] 1.00 [ref] 1.00 [ref] 1.00 [ref]
2 490 34.0% 1.01 (0.79, 1.28) -0.43 (-1.31, 0.46) 0.79 (0.62, 1.01) -0.81 (-1.53, -0.09)
3 515 35.8% 1.03 (0.80, 1.31) -0.37 (-1.25, 0.51) 0.64 (0.49, 0.83) -1.26 (-1.98, -0.54)
4/5 320 22.2% 0.94 (0.71, 1.25) -0.81 (-1.76, 0.13) 0.57 (0.40, 0.81) -1.57 (-2.34, -0.80)
SNAP score (continuous) 0.98 (0.91, 1.06) -0.20 (-0.45, 0.04) 0.83 (0.75, 0.92) -0.44 (-0.64, -0.24)
P Trend 0.62 0.10 <0.001 <0.001
All models adjusted for age, sex, Patient-Determined Disease Steps score, depression or anxiety treatment, fatigue level, education level and 
socioeconomic status.
Boldface values denote statistical significance (p<0.05).
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Figure 1. Venn diagram showing the co-occurrence of lifestyle risk factors. 
130x129mm (150 x 150 DPI) 
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Supplementary Table 1. Prevalence and co-occurrence of SNAP protective factors.
SNAP 
score
SNAP score 
prevalence
Pattern 
prevalence
N % N %
Non-
Smoker
Healthy 
diet
Non-
hazardous 
alcohol 
consumption
Adequate 
physical 
activity
Healthy 
BMI
0 11 0.8%
1 44 42.3% 
1 1 1.0% 
1 104 7.2% 36 34.6% 
1 10 9.6% 
1 13 12.5% 
2 1 0.2%  
2 319 65.1%  
2 92 18.8%  
2 23 4.7%  
2 490 34.0% 0 0.0%  
2 0 0.0%  
2 0 0.0%  
2 24 4.9%  
2 21 4.3%  
2 10 2.0%  
3 20 3.9%   
3 0 0.0%   
3 0 0.0%   
3 0 0.0%   
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3 515 35.8% 39 7.6%   
3 162 31.5%   
3 272 52.8%   
3 1 0.2%   
3 5 1.0%   
3 16 3.1%   
4 2 0.7%    
4 201 72.3%    
4 278 19.3% 1 0.4%    
4 24 8.6%    
4 50 18.0%    
5 42 2.9%     
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